4.8 Article

Platelet-Microcapsule Hybrids Leverage Contractile Force for Targeted Delivery of Hemostatic Agents

期刊

ACS NANO
卷 11, 期 6, 页码 5579-5589

出版社

AMER CHEMICAL SOC
DOI: 10.1021/acsnano.7b00929

关键词

targeted drug delivery; hemophilia A; factor VIII; platelet contraction; cell-mediated; polyelectrolyte multilayer microcapsule; hemostatic agents

资金

  1. NIH [RO1 (HL121264), RO1 (HL130918), U54 (HL112309)]
  2. NSF CAREER [1150235]
  3. DoD U.S. Army Medical Research and Material Command [W81XWH-13-1-0495]
  4. Children's Healthcare of Atlanta's Center for Pediatric Nanomedicine
  5. Div Of Chem, Bioeng, Env, & Transp Sys
  6. Directorate For Engineering [1150235] Funding Source: National Science Foundation

向作者/读者索取更多资源

We report a cell-mediated, targeted drug delivery system utilizing polyelectrolyte multilayer capsules that hybridize with the patient's own platelets upon intravenous administration. The hybridized platelets function as the sensor and actuator for targeted drug delivery and controlled release in our system. These capsules are biochemically and mechanically tuned to enable platelet adhesion and capsule rupture upon platelet activation and contraction, enabling the targeted and controlled burst release of an encapsulated biotherapeutic. As platelets are the first responders in the blood clot formation process, this platelet-hybridized system is ideal for the targeted delivery of clot-augmenting biotherapeutics wherein immediate therapeutic efficacy is required. As proof-of-concept, we tailored this system to deliver the pro-clotting biotherapeutic factor VIII for hemophilia A patients that have developed inhibitory antifactor VIII antibodies. The polyelectrolyte multilayer capsules physically shield the encapsulated factor VIII from the patient's inhibitors during circulation, preserving its bioactivity until it is delivered at the target site via platelet contractile force. Using an in vitro microfluidic vascular injury model with factor VIII-inhibited blood, we demonstrate a 3.8X increase in induced fibrin formation using capsules loaded with factor VIII at a concentration an order of magnitude lower than that used in systemic delivery. We further demonstrate that clot formation occurs 18 min faster when factor VIII loaded capsules are used compared to systemic delivery at the same concentration. Because platelets are integral in the pathophysiology of thrombotic disorders, cancer, and innate immunity, this paradigm-shifting smart drug delivery system can be similarly applied to these diseases.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据